The Medicines Company’s Leadership Team has extensive commercial and scientific expertise in developing and delivering innovative cardiovascular therapies to healthcare providers and their patients. That experience is bolstered by deep relationships with industry-leading experts, proven leadership capabilities and strong business skills.
The Medicines Company
Mark TimneyChief Executive Officer
Mark Timney joined The Medicines Company in December 2018 as Chief Executive Officer and as a Director. Mark is a healthcare leader with over 25 years of biopharmaceutical industry experience in multi-national companies. At Merck & Co, Mark led organizations of increasing importance and size, including President US, President Japan and President of Global Primary Care. In these roles, he launched multiple products, many in the cardiovascular therapeutic area, led large organizations of up to 8,000 employees, and was involved in a number of important strategic transactions. After leaving Merck, Mark served as the CEO of Purdue Pharmaceuticals and formed a company advising healthcare companies. Before joining Merck, he spent 8 years working at numerous multinational pharmaceutical companies, including Zeneca Group, ICI Pharmaceuticals and Roussel Labs. Mark received a bachelor’s degree in Sports Studies (majoring in Marketing) from Newcastle Polytechnic (now Northumbria University) in Newcastle in the United Kingdom.
Chris VisioliChief Finance Officer
Christopher Visioli joined The Medicines Company in June 2003 and has served as the company’s Chief Financial Officer since March 2018. He has worked in a variety of leadership roles in the organization including business development, finance, investor relations, strategy, planning, and general management overseeing cardiovascular care products. He has led many efforts in the organization to acquire products and establish partnerships, in addition to leading long-term strategy and financial planning work. Prior to joining the company, Chris was a management consultant for Ernst & Young. Chris holds a bachelor’s in Electrical Engineering from Cornell University and an MBA from Columbia Business School.
Richard FiresChief Human Strategy Officer
Richard Fires joined The Medicines Company in October 2006 and has served as the company’s Chief Human Strategy Officer, Senior Vice President, Human Strategy, since [February 2018], where his accountabilities include human resource management, human and compensation strategies, change management, team building and meeting facilitation. He has held multiple roles spanning the Human Strategy organization, including supporting an expanded field sales organization and growing lines of business. Prior to that, he spent 10 years in different human resources roles in the consumer-packaged goods industry with category leaders, including Mars Inc. and ConAgra Foods Inc. Richard holds a bachelor’s in Human Resource Management from Bellevue University and an MBA from the University of Nebraska, along with multiple Human Resources certifications.
Clive Meanwell, MD PhDChief Innovation Officer
Clive Meanwell founded The Medicines Company and has been a Director since its inception in 1996. Clive has served as the company’s Chief Innovation Officer since December 2018. Previously, he served as the company’s Chief Executive Officer from August 2004 to December 2018, President from August 2004 to December 2004, Executive Chairman from September 2001 to August 2004 and Chief Executive Officer and President from 1996 to September 2001. Clive was also the company’s Chairman of Board from September 2001 to August 2015. From 1995 to 1996, Clive was a Partner and Managing Director at MPM Capital, L.P., a venture capital firm. From 1986 to 1995, Clive held various positions at Hoffmann-La Roche, Inc., a pharmaceutical company, including Senior Vice President from 1992 to 1995, Vice President from 1991 to 1992 and Director of Product Development from 1986 to 1991. Clive received an M.D. (British equivalent MB ChB) and a Ph.D. (British equivalent MD hons) from the University of Birmingham, United Kingdom.
Stephen RodinExecutive Vice President and General Counsel
Stephen Rodin joined The Medicines Company in October 2007 and has served as the company’s General Counsel and Secretary since March 2014. Previously he served as the company's Deputy General Counsel from 2010 to 2014 and Associate General Counsel from 2007 to 2010. Before joining the company, Steve was an attorney at the law firm of Proskauer Rose LLP in New York where his practice focused on corporate, commercial and securities law. Steve received a bachelor’s in English from Georgetown University and his J.D. from Vanderbilt University Law School.
Diane SullivanChief Commercial Officer
Diane Sullivan joined The Medicines Company in December 2018 as Chief Commercial Officer. Diane is an accomplished commercial executive with extensive leadership experience and proven success in life sciences (AstraZeneca, Pfizer, GlaxoSmithKline), consumer healthcare (GlaxoSmithKline) and technology (IBM) at US- and UK-based global corporations. She has launch and in-line experience from rare disease to blockbusters in most therapeutic areas and has had responsibility for sales of $20B for 500+ customer relationships. Prior to her current role, she was Vice President of Market Access & Patient Strategies at AstraZeneca and prior to that, she was Vice President, Specialty Care Payer & Channel Group at Pfizer, where she gained expertise in specialty leading the strategy for business-to-business customers. Before the acquisition by Pfizer, she was Vice President of Health Systems Marketing at Wyeth. Prior to joining Wyeth, Diane was Executive Director, Worldwide Business Development and Strategy at GlaxoSmithKline (GSK) in the Consumer Healthcare Business. Diane currently serves on the Board of OrthogenRx. Diane began her career at IBM where she graduated from IBM’s MBA program. She has bachelor’s in French from Dickinson College.
Peter Wijngaard, PhDChief Development Officer
Peter Wijngaard joined The Medicines Company in February 2011 and has been Chief Development Officer since January 2018, leading the company’s ORION development program and medical affairs teams. Peter has extensive experience in the areas of global project leadership, business development, medical affairs, and pharmaceutical marketing. He has also published extensively in the area of transplant immunology and immunosuppression, with an emphasis on the use of mycophenolate mofetil (CellCept®). Previously, Peter led European Medical Affairs and Development at ViroPharma Inc, and has held various positions at Hoffmann-La Roche, including International Medical Manager and Lifecycle Leader for the transplantation portfolio, as well as Global Alliance Director managing the Genentech alliance. Peter was also a member of the Roche Organ Transplant Research Foundation Board. Peter served on the Board of Directors of Isotechnika Pharmaceuticals Inc, Aurinia Pharmaceuticals Inc and Ciclofilin Pharmaceuticals Inc. Peter has a PhD in Transplantation Immunology from Utrecht University, the Netherlands.